Published in Dev Cell on February 01, 2003
Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol (2006) 4.32
The stem cell niches in bone. J Clin Invest (2006) 4.11
Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med (2006) 3.09
Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood (2008) 2.79
The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A (2004) 2.53
Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood (2005) 2.05
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood (2007) 1.61
Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol (2008) 1.54
HOXB4's road map to stem cell expansion. Proc Natl Acad Sci U S A (2007) 1.43
Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia. Proc Natl Acad Sci U S A (2005) 1.35
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia (2009) 1.33
Artificial stem cell niches. Adv Mater (2009) 1.11
Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. J Exp Med (2004) 1.06
Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY) (2011) 1.02
Intercellular network structure and regulatory motifs in the human hematopoietic system. Mol Syst Biol (2014) 0.96
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood (2014) 0.94
FGF signaling facilitates postinjury recovery of mouse hematopoietic system. Blood (2012) 0.92
Growth factor receptors as regulators of hematopoiesis. Blood (2006) 0.88
TGF-β/Smad3 stimulates stem cell/developmental gene expression and vascular smooth muscle cell de-differentiation. PLoS One (2014) 0.86
A crucial interaction between embryonic red blood cell progenitors and paraxial mesoderm revealed in spadetail embryos. Dev Cell (2004) 0.86
Engineering approaches toward deconstructing and controlling the stem cell environment. Ann Biomed Eng (2011) 0.83
Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood (2012) 0.83
FGF signalling restricts haematopoietic stem cell specification via modulation of the BMP pathway. Nat Commun (2014) 0.82
Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget (2016) 0.80
Copper modulates the differentiation of mouse hematopoietic progenitor cells in culture. Cell Transplant (2009) 0.79
FGF signalling specifies haematopoietic stem cells through its regulation of somitic Notch signalling. Nat Commun (2014) 0.79
Angiopoietin-like protein 3 promotes preservation of stemness during ex vivo expansion of murine hematopoietic stem cells. PLoS One (2014) 0.78
Protein tyrosine phosphatase-σ regulates hematopoietic stem cell-repopulating capacity. J Clin Invest (2014) 0.77
JAK2(V617F)-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia (2016) 0.76
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res (2016) 0.75
Bone Niches, Hematopoietic Stem Cells, and Vessel Formation. Int J Mol Sci (2017) 0.75
The telomere binding protein Pot1 maintains haematopoietic stem cell activity with age. Nat Commun (2017) 0.75
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet (2005) 6.91
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Genetical genomics: spotlight on QTL hotspots. PLoS Genet (2008) 2.63
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med (2006) 2.18
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
Expression quantitative trait loci are highly sensitive to cellular differentiation state. PLoS Genet (2009) 1.92
A Limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells (2006) 1.84
Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood (2010) 1.81
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
Asymmetry in skeletal distribution of mouse hematopoietic stem cell clones and their equilibration by mobilizing cytokines. J Exp Med (2014) 1.52
Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci U S A (2002) 1.50
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation (2005) 1.48
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid (2002) 1.44
Engraftment of syngeneic bone marrow is not more efficient after intrafemoral transplantation than after traditional intravenous administration. Exp Hematol (2010) 1.44
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica (2009) 1.39
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood (2003) 1.39
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol (2007) 1.39
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood (2006) 1.39
Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice. Blood (2002) 1.38
Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells (2005) 1.35
Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol (2008) 1.33
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci (2012) 1.25
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
A statistical multiprobe model for analyzing cis and trans genes in genetical genomics experiments with short-oligonucleotide arrays. Genetics (2005) 1.25
Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood (2009) 1.24
Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcoding. Blood (2013) 1.23
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood (2007) 1.23
Isolation and characterization of human salivary gland cells for stem cell transplantation to reduce radiation-induced hyposalivation. Radiother Oncol (2009) 1.21
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (2010) 1.21
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood (2010) 1.20
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization. Proc Natl Acad Sci U S A (2006) 1.17
Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood (2002) 1.17
Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat Cell Biol (2013) 1.16
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun (2005) 1.16
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol (2007) 1.16
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood (2004) 1.14
A genetic and genomic analysis identifies a cluster of genes associated with hematopoietic cell turnover. Blood (2002) 1.13
Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood (2011) 1.13
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood (2013) 1.11
Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol (2005) 1.11
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol (2003) 1.10
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol (2003) 1.10
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica (2007) 1.09
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol (2013) 1.09
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica (2011) 1.09
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood (2007) 1.08
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol (2009) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells. Exp Cell Res (2002) 1.07
Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood (2011) 1.07
Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J Immunol (2007) 1.07
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet (2006) 1.07
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood (2010) 1.06